NEWS RELEASE

FOR IMMEDIATE RELEASE

November 16, 2026

the MORE LIFE COMPANY

THE MORE LIFE COMPANY ADVANCES AGRARIUS COMMERCIAL ADOPTION FOR 384,000 CITRUS TREES IN BRAZIL

Third-party FARMATAC findings and reported harvest gains support commercial adoption

Toronto, Ontario, November 16, 2026, The More Life Company Corp. (the "Company" or "MLCO"), (CSE: MLCO) (OTC: TMLCF) is pleased to announce that a Brazilian citrus grower whose orchards hosted the Agrarius™ trials has placed an initial order for a planned commercial application program covering approximately 384,000 citrus trees. The order follows positive results from FARMATAC's second-cycle pre-harvest assessment and production gains documented in the grower's main-harvest records. FARMATAC, the third-party agricultural research partner engaged by the grower, conducted assessments across both evaluation cycles.

"A grower's decision to move from successful evaluations to a planned program covering 384,000 trees is a meaningful first step in the commercialization of Agrarius," stated Dennis Hancock, President and Chief Executive Officer of The More Life Company. "The third-party findings from FARMATAC and the reported harvest gains give us a strong basis for further grower discussions. Our priority is to translate that evidence into lasting commercial relationships built around measurable agricultural value."

Building on the citrus results announced on December 1, 2025, from FARMATAC's first evaluation cycle, FARMATAC's pre-harvest sampling assessment estimated Hamlin yield of 1,657.9 boxes per hectare in the Agrarius-treated area compared with 981.3 boxes per hectare under the farm's standard management without Agrarius, an estimated increase of approximately 69%. The assessment included both fruit approaching harvest and fruit expected to mature later in the season.

Separately, the grower's 2026 main-harvest records showed production of 1,041 boxes per hectare in the Agrarius-treated area compared with 710 boxes per hectare under standard management without Agrarius, an additional 331 boxes per hectare, or approximately 46.6%. The pre-harvest estimates and main-harvest production represent distinct assessments of orchard performance, with the estimates also accounting for later-maturing fruit that growers may be able to capitalize on through adjustments to tree formation and harvest management.

In the same pre-harvest assessment, FARMATAC reported a 62.7% increase in estimated concentrated-juice output per hectare, with approximately 4.1 tonnes per hectare in the Agrarius-treated area compared with approximately 2.5 tonnes per hectare in the comparison area. The difference was statistically significant within the assessment.

"Productivity was statistically impacted by the treatment with Agrarius," stated FARMATAC. "The Agrarius product has the potential to promote significant improvements in root development, plant formation, and overall productivity, and can therefore be utilized in citrus crop management."

ORCHARD DEVELOPMENT AND SUSTAINED PRODUCTIVITY

The broader citrus assessments indicated stronger root development, improved tree formation, and better flowering and fruit set throughout the production cycle. The Company believes that, together with the recorded yield gains, these findings support the potential for higher peak productivity and a longer economically productive orchard life.

The production gains were achieved in an orchard affected by Huanglongbing (HLB), also known as citrus greening, which the Company believes indicates Agrarius's ability to support production under the conditions evaluated. Sustained productivity gains could help extend the economically productive life of affected trees.

The Company is not claiming that Agrarius treats or cures HLB. The reported results relate to orchard productivity under the conditions evaluated.

ADVANCING CITRUS COMMERCIALIZATION IN LATIN AMERICA

"The production gains achieved in Brazil give us a compelling basis to expand Agrarius within Latin America's citrus sector," said Spiros Fournogerakis, Vice President of Operations of The More Life Company. "The grower's decision to proceed commercially reinforces the value of these results. Our focus is on securing additional grower commitments and expanding commercial application, supported by the agronomic expertise needed to integrate Agrarius into established orchard management programs. We see a significant opportunity to increase output from existing orchards and build sustained demand for Agrarius."

Citrus growers and agronomic partners interested in reviewing the results or discussing an orchard evaluation are invited to contact info@themorelife.company with the subject line "Agrarius Citrus".

ABOUT AGRARIUS™

Agrarius™ is the Company's licensed agricultural plant signaling technology, designed to be applied to crops to support productivity, nutrient use and plant performance. The Company's commercialization approach combines field evaluation, agronomic support and grower relationships to assess the product's potential across agricultural crops and operating conditions.

ABOUT THE MORE LIFE COMPANY CORP.

The More Life Company Corp., formerly Mountain Valley MD Holdings Inc., is building a world-class organization centered around the implementation, licensing and reselling of key technologies and formulations:

- patented Quicksome™ oral formulation and delivery technologies;
- patented Quicksol™ solubility formulation technology; and
- licensed product reseller of Agrarius™, a novel agricultural plant signaling technology.

Consistent with its vision towards "More Life", the Company applies its owned and licensed technologies to its work for advanced delivery of molecules for human and husbandry animal applications, including the development of products for pain management, weight loss, energy, focus, sleep, anxiety, and more. Additionally, the Company's work with Agrarius is focused on generating a positive impact on crop yields and reducing fertilizer usage.

The Company's patented Quicksome™ technology utilizes proprietary formulations and stabilizing molecules to encapsulate and formulate active ingredients into highly efficient product formats. The result is a new generation of product formulations that could be capable of delivering nutraceutical and drug molecules into the body faster, with greater impact, efficiency and accuracy.

The Company's patented Quicksol™ technology covers all highly solubilized macrocyclic lactones that could be effectively applied in multiple viral applications that could positively impact human and animal health globally.

The Company's licensed Agrarius™ agricultural plant signaling technology is designed to be applied to crops to naturally increase yields, reduce fertilizer usage, and increase general resilience to pests and climate change.

For more Company information and contact details, visit www.themorelife.company.

SOURCE: THE MORE LIFE COMPANY CORP.

themorelife.company

For further information:

Dennis Hancock
President and Chief Executive Officer
The More Life Company Corp.
Investor Relations: 647-725-9755
Email: info@themorelife.company

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION

Certain statements contained in this news release may constitute forward-looking information within the meaning of applicable securities laws. Forward-looking information is often, but not always, identified by words such as "anticipate", "believe", "continue", "estimate", "expect", "intend", "may", "plan", "potential", "should", "will" and similar expressions, or statements that events, conditions or results "can", "could", "may", "should" or "will" occur or be achieved.

Forward-looking information contained in this news release includes statements regarding the fulfilment of the initial order and implementation of the planned commercial application program covering approximately 384,000 citrus trees; progression from field evaluation to commercial adoption; engagement with citrus growers and agronomic partners, orchard evaluations and commercial application programs; the expansion of Agrarius within Latin America's citrus sector and the opportunity to increase output from existing orchards and build sustained demand; the potential for Agrarius to support root development, tree formation, flowering, fruit set, late-season production and higher peak productivity; the potential to support production in HLB-affected orchards; whether sustained productivity gains could extend economically productive orchard life; and the potential agricultural and commercial benefits of Agrarius.

Forward-looking information is based on management's current expectations, assumptions and beliefs, including that the anticipated purchase and application program will proceed, product will be available, the reported results are representative of Agrarius's performance under similar conditions, the Company's licensor will continue to supply the product, and field experience will support further grower interest. Actual results may differ materially due to factors including customer purchasing decisions, commercial terms and performance conditions, weather, disease pressure, the progression of HLB, orchard characteristics, agricultural practices, product

performance, the limitations of a single orchard trial and of estimated results, regulatory requirements, market acceptance and the availability of capital and other resources.

There can be no assurance that the anticipated purchase will be completed on the timing or terms expected, that field results will be reproduced in other orchards or future seasons, that Agrarius will support production in HLB-affected orchards, or that grower discussions will result in commercial arrangements. Reported yield results do not assure future grower returns or Company revenue.

Readers are cautioned not to place undue reliance on forward-looking information. Any forward-looking information contained in this news release represents the Company's expectations as of the date hereof and is subject to change after such date. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities legislation.

Neither the CSE nor OTC Markets Group has reviewed or approved the contents of this press release.